Rydar Equities’s Aquestive Therapeutics AQST Stock Holding History

Rydar Equities’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$97	Buy	+21	New	+$93	﹤0.01%	435

Other funds holding AQST

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

SMAM

Sugar Maple Asset Management Sister Bay, Wisconsin $175M AUM 16.33% 1-Year Est. Return

Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return

ACA

Adirondack Capital Advisors Syracuse, New York $194M AUM 14.02% 1-Year Est. Return

CCM

Cox Capital Management Andover, Massachusetts $179M AUM 28.94% 1-Year Est. Return

Lineweaver Wealth Advisors Valley View, Ohio $863M AUM 14.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Rydar Equities's AQST Position: Q3 2026 in Review

Rydar Equities opened a new position in Aquestive Therapeutics (AQST) in Q3 2026: 21 shares worth $97. The stake represents ﹤0.01% of the portfolio and ranks #435 among its holdings.

13 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Rydar Equities held 21 shares of Aquestive Therapeutics worth $97 as of Q3 2026.
Aquestive Therapeutics was a new Rydar Equities position in Q3 2026.
Aquestive Therapeutics made up ﹤0.01% of Rydar Equities's portfolio in Q3 2026, its #435 holding.
13 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.